gms | German Medical Science

131. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

25.03. - 28.03.2014, Berlin

Article

Send article

Crohn’s disease and ulcerative colitis: 10-year prevalence and inpatient care

Meeting Abstract

Search Medline for

  • Rebecca Hein - Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, PMV research group, Köln
  • Ingrid Köster - Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, PMV research group, Köln
  • Elfriede Bollschweiler - Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, PMV research group, Köln
  • Ingrid Schubert - Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, PMV research group, Köln

Deutsche Gesellschaft für Chirurgie. 131. Kongress der Deutschen Gesellschaft für Chirurgie. Berlin, 25.-28.03.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc14dgch445

doi: 10.3205/14dgch445, urn:nbn:de:0183-14dgch4452

Published: March 21, 2014

© 2014 Hein et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Introduction: A worldwide increase in the prevalence of Crohn’s disease (CD) und ulcerative colitis (UC) over the past 50 years has been reported. Respective data for Germany are scarce. This study investigates the CD/UC prevalence in Germany in the years 2001 to 2010 and describes the health care utilisation of CD/UC patients of the year 2010 in the inpatient sector.

Material and methods: Data base: statutory health insurance sample AOK Hesse/KV Hesse (18.75% random sample of 1.5 m insurants). Study population: individuals continuously insured in the respective year (in 2001 to 2010 N=265,102 to 311,001). Prevalent CD/UC cases: insurants with internally validated CD/UC diagnosis (CD: ICD-10-Code K50, in 2001 to 2010 N=486 to 627, UC: ICD-10-Code K51, in 2001 to 2010 N=642 to 749). Controls: insurants without CD/UC diagnosis in IV/2009 and 2010, 1:4 matching of cases and controls with respect to age and sex. Direct standardisation of the administrative CD/UC prevalence of the years 2001 to 2010 by age and sex. Evaluation of the change in prevalence over the years by means of age and sex adjusted Poisson regression. Extrapolation of CD/UC case numbers with respect to age and sex to the population of Germany. Conditional logistic regression to compare cases and controls with respect to inpatient health care utilisation. Level of significance 0.05.

Results: Our study shows a highly significant increase of CD/UC prevalence: for CD from 166 cases per 100,000 insurants in 2001 to 247 cases per 100,000 insurants in 2010 (p=4.1x10-15); for UC from 197 cases per 100,000 insurants in 2001 to 272 cases per 100,000 insurants in 2010 (p=1.1x10-11). Correspondingly, the number of CD/UC cases in Germany increased: for CD from 137,076 in 2001 to 202,285 in 2010; for UC from 162,628 in 2001 to 222,684 in 2010. With respect to health care utilisation of CD/UC patients in the inpatient sector, we observed a significantly higher percentage of cases versus controls with fully inpatient hospital stays (CD: 31% versus 14%, p=2.8x10-21; UC: 31% versus 18%, p=3.3x10-15). Disease specific diagnostic procedures were conducted among 10%/7% of CD/UC cases. Furthermore, 3%/1% of CD/UC patients underwent disease specific surgeries.

Conclusion: For the first time, our study shows a highly significant increase in CD/UC prevalence for Germany, which is in line with results presented in the international literature. Along with the comparatively high number of fully inpatient hospital stays among CD/UC patients, the observed increase in patient numbers indicates non-negligible financial implications for the health care system.

The study was financed by an unrestricted grant from AbbVie Deutschland GmbH & Co. KG.